We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.


We are a clinical stage biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding. We execute a clear strategy around the three pillars of Alzheimer's disease, other significant and neuro-orphan indications and diagnosis.

Our two proprietary technology platforms allow us to discover, design and develop antibodies, small molecules and vaccines. These platforms are the engines for our diverse pipeline of product candidates, which currently consists of nine therapeutic product candidates with four in clinical trials and three diagnostic candidates. Our lead product candidate is crenezumab, an anti-Abeta antibody being developed in phase 3 for Alzheimer’s disease by our collaboration partner Genentech. We believe that our multiple strategic alliances with leading industry partners like Genentech, Janssen, Piramal, Nestlé Institute of Health Sciences, Biogen and Essex Bio-Technology provide external validation of our Company and the quality of our science.

Our Investor Center is designed to provide you with convenient access to information about our Company.

Stock quote

Copyright West LLC. Minimum 15 minutes delayed.